{"title":"巴布亚省三个县的居民体内艾滋病毒抗逆转录病毒耐药性(ODHA)的突变病例","authors":"H. Hutapea","doi":"10.22435/BPK.V46I3.902","DOIUrl":null,"url":null,"abstract":"Antiretroviral (ARV) therapy has been found effective to decrease HIV-1 infected cases, however increase the resistances due to nucleotide mutation. The mutation causes virus to be resistant to ARV, making the therapy is no longer effective. The ARV therapy District Nabire, Jayapura, and Jayawijaya was Reverse Transcriptase Inhibitor (RTI). The goal of this study was to obtain the data of mutation associated to viral resistance to ARV RTI and protease inhibitor group. Plasma samples were obtained from 252 subjects purposively in HIV/AIDS population from corresponding Care, Support, and Therapy clinic. The genotyping, measurement of CD4 and viral load were performed to all samples. DNA analysis was performed by genotyping method. Among 252 samples, 89 samples (35.32%) had CD4 count <350 sel/ul. Twenty three samples (8.73%) had viral load >10.000 copies/mL. There were 15 (5,95%) samples were identified as mutant related to RTI resistance, and none for protease. The most frequent mutation motive was M184V/I, 12 samples (80,00%). This data provided important information about the continuous need of ARV therapy monitoring to suppress transmission drug resistance. \n \nAbstrak \nPenemuan antiretroviral (ARV) secara signifikan telah menjadi bagian penting dalam penanggulangan HIV/AIDS. Terapi ARV dilakukan untuk menurunkan kasus HIV-1, namun dapat menyebabkan resistensi virus terhadap ARV tersebut. Data prevalensi HIV-1 resisten ARV pada Orang Dengan HIV/AIDS (ODHA) di Papua, khususnya Kabupaten Nabire, Kab./Kota Jayapura, dan Kab. Jayawijaya belum tersedia. Tujuan penelitian ini adalah untuk mendapatkan data prevalensi mutasi terkait resistensi virus terhadap ARV golongan penghambat rtase dan protease. Sebanyak 84 responden yang sudah diterapi minimal 6 bulan diambil secara purposive dari setiap lokasi penelitian. Genotyping, pemeriksaan nilai CD4 dan viral load dilakukan terhadap semua sampel. Analisis DNA dilakukan dengan metode genotyping. Dari 252 sampel, sebanyak 89 responden (35,32%) memiliki nilai CD4 <350 sel/ul darah. Sebanyak 23 responden (8,73%) memiliki nilai viral load >10.000 salinan/mL. Sebanyak 15 sampel (5,95%) teridentifikasi mengalami mutasi pada DNA target ARV golongan penghambat rtase, dan tidak ditemukan mutasi terkait resistensi pada gen protease. Motif mutasi yang paling banyak adalah M184V/I, yaitu sebanyak 12 sampel (80,00%). Penelitian ini mengindikasikan bahwa pemantauan terapi ARV secara berkesinambungan tetap diperlukan untuk menekan penulan HIV resisten ARV. \n ","PeriodicalId":41475,"journal":{"name":"Buletin Penelitian Kesehatan","volume":"3 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2018-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Gambaran Kasus Mutasi Terkait Resistensi Antiretroviral pada orang dengan HIV-AIDS (ODHA) di Tiga Kabupaten/Kota di Provinsi Papua\",\"authors\":\"H. Hutapea\",\"doi\":\"10.22435/BPK.V46I3.902\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antiretroviral (ARV) therapy has been found effective to decrease HIV-1 infected cases, however increase the resistances due to nucleotide mutation. The mutation causes virus to be resistant to ARV, making the therapy is no longer effective. The ARV therapy District Nabire, Jayapura, and Jayawijaya was Reverse Transcriptase Inhibitor (RTI). The goal of this study was to obtain the data of mutation associated to viral resistance to ARV RTI and protease inhibitor group. Plasma samples were obtained from 252 subjects purposively in HIV/AIDS population from corresponding Care, Support, and Therapy clinic. The genotyping, measurement of CD4 and viral load were performed to all samples. DNA analysis was performed by genotyping method. Among 252 samples, 89 samples (35.32%) had CD4 count <350 sel/ul. Twenty three samples (8.73%) had viral load >10.000 copies/mL. There were 15 (5,95%) samples were identified as mutant related to RTI resistance, and none for protease. The most frequent mutation motive was M184V/I, 12 samples (80,00%). This data provided important information about the continuous need of ARV therapy monitoring to suppress transmission drug resistance. \\n \\nAbstrak \\nPenemuan antiretroviral (ARV) secara signifikan telah menjadi bagian penting dalam penanggulangan HIV/AIDS. Terapi ARV dilakukan untuk menurunkan kasus HIV-1, namun dapat menyebabkan resistensi virus terhadap ARV tersebut. Data prevalensi HIV-1 resisten ARV pada Orang Dengan HIV/AIDS (ODHA) di Papua, khususnya Kabupaten Nabire, Kab./Kota Jayapura, dan Kab. Jayawijaya belum tersedia. Tujuan penelitian ini adalah untuk mendapatkan data prevalensi mutasi terkait resistensi virus terhadap ARV golongan penghambat rtase dan protease. Sebanyak 84 responden yang sudah diterapi minimal 6 bulan diambil secara purposive dari setiap lokasi penelitian. Genotyping, pemeriksaan nilai CD4 dan viral load dilakukan terhadap semua sampel. Analisis DNA dilakukan dengan metode genotyping. Dari 252 sampel, sebanyak 89 responden (35,32%) memiliki nilai CD4 <350 sel/ul darah. Sebanyak 23 responden (8,73%) memiliki nilai viral load >10.000 salinan/mL. Sebanyak 15 sampel (5,95%) teridentifikasi mengalami mutasi pada DNA target ARV golongan penghambat rtase, dan tidak ditemukan mutasi terkait resistensi pada gen protease. Motif mutasi yang paling banyak adalah M184V/I, yaitu sebanyak 12 sampel (80,00%). Penelitian ini mengindikasikan bahwa pemantauan terapi ARV secara berkesinambungan tetap diperlukan untuk menekan penulan HIV resisten ARV. \\n \",\"PeriodicalId\":41475,\"journal\":{\"name\":\"Buletin Penelitian Kesehatan\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2018-12-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Buletin Penelitian Kesehatan\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22435/BPK.V46I3.902\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Buletin Penelitian Kesehatan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22435/BPK.V46I3.902","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
摘要
抗逆转录病毒(ARV)治疗已被发现对减少HIV-1感染病例有效,但由于核苷酸突变而增加耐药性。这种突变导致病毒对ARV产生耐药性,使治疗不再有效。ARV治疗区Nabire, Jayapura和Jayawijaya是逆转录酶抑制剂(RTI)。本研究的目的是获得病毒对ARV RTI和蛋白酶抑制剂组耐药相关的突变数据。从相应的护理、支持和治疗诊所有目的地采集了252名HIV/AIDS人群的血浆样本。对所有样本进行基因分型、CD4和病毒载量测定。采用基因分型法进行DNA分析。252份样本中,89份(35.32%)CD4计数为10000拷贝/mL。有15个(5.95%)样本被鉴定为与RTI耐药相关的突变体,而蛋白酶没有突变体。最常见的突变动机为M184V/I, 12份(8000%)。这一数据提供了重要信息,说明需要持续监测抗逆转录病毒治疗以抑制传播耐药性。摘要/ abstract摘要:抗逆转录病毒(ARV)治疗艾滋病具有重要意义。Terapi ARV -1,即Terapi ARV -1耐药病毒。艾滋病毒-1耐药抗逆转录病毒病毒数据流行情况:巴布亚新几内亚,khususnya, Kabupaten, Nabire, Kab,艾滋病毒/艾滋病(ODHA)。/Kota Jayapura, dan Kab。菊花。图juan penelitian ini adalah untuk mendapatkan数据流行于mutasi terkai耐药病毒terhadap ARV高龙安penghambat释放酶和蛋白酶。2004年答复者杨苏达(yang sudah)说:“有目的的、有目的的、不确定的、不确定的、不确定的、不确定的。”基因分型、外周血淋巴细胞CD4和病毒载量。DNA dilakukan dengan方法基因分型分析。Dari 252例,sebanyak 89例(35.32%),CD4 1万salinan/mL。Sebanyak 15样品(5.95%)鉴定出ARV靶基因goongan penghambat酶,但鉴定出mutasi terkait耐药pada酶。Motif mutasi yang paling banyak adalah M184V/I, yitu sebanyak 12样品(80%,00%)。耐艾滋病病毒的抗逆转录病毒药物(ARV)。
Gambaran Kasus Mutasi Terkait Resistensi Antiretroviral pada orang dengan HIV-AIDS (ODHA) di Tiga Kabupaten/Kota di Provinsi Papua
Antiretroviral (ARV) therapy has been found effective to decrease HIV-1 infected cases, however increase the resistances due to nucleotide mutation. The mutation causes virus to be resistant to ARV, making the therapy is no longer effective. The ARV therapy District Nabire, Jayapura, and Jayawijaya was Reverse Transcriptase Inhibitor (RTI). The goal of this study was to obtain the data of mutation associated to viral resistance to ARV RTI and protease inhibitor group. Plasma samples were obtained from 252 subjects purposively in HIV/AIDS population from corresponding Care, Support, and Therapy clinic. The genotyping, measurement of CD4 and viral load were performed to all samples. DNA analysis was performed by genotyping method. Among 252 samples, 89 samples (35.32%) had CD4 count <350 sel/ul. Twenty three samples (8.73%) had viral load >10.000 copies/mL. There were 15 (5,95%) samples were identified as mutant related to RTI resistance, and none for protease. The most frequent mutation motive was M184V/I, 12 samples (80,00%). This data provided important information about the continuous need of ARV therapy monitoring to suppress transmission drug resistance.
Abstrak
Penemuan antiretroviral (ARV) secara signifikan telah menjadi bagian penting dalam penanggulangan HIV/AIDS. Terapi ARV dilakukan untuk menurunkan kasus HIV-1, namun dapat menyebabkan resistensi virus terhadap ARV tersebut. Data prevalensi HIV-1 resisten ARV pada Orang Dengan HIV/AIDS (ODHA) di Papua, khususnya Kabupaten Nabire, Kab./Kota Jayapura, dan Kab. Jayawijaya belum tersedia. Tujuan penelitian ini adalah untuk mendapatkan data prevalensi mutasi terkait resistensi virus terhadap ARV golongan penghambat rtase dan protease. Sebanyak 84 responden yang sudah diterapi minimal 6 bulan diambil secara purposive dari setiap lokasi penelitian. Genotyping, pemeriksaan nilai CD4 dan viral load dilakukan terhadap semua sampel. Analisis DNA dilakukan dengan metode genotyping. Dari 252 sampel, sebanyak 89 responden (35,32%) memiliki nilai CD4 <350 sel/ul darah. Sebanyak 23 responden (8,73%) memiliki nilai viral load >10.000 salinan/mL. Sebanyak 15 sampel (5,95%) teridentifikasi mengalami mutasi pada DNA target ARV golongan penghambat rtase, dan tidak ditemukan mutasi terkait resistensi pada gen protease. Motif mutasi yang paling banyak adalah M184V/I, yaitu sebanyak 12 sampel (80,00%). Penelitian ini mengindikasikan bahwa pemantauan terapi ARV secara berkesinambungan tetap diperlukan untuk menekan penulan HIV resisten ARV.